Schrodinger (SDGR) on Thursday reported Phase 1 trial data showing a 22% overall response rate for its investigational monotherapy SGR-1505 in patients with relapsed or refractory B-cell malignancies.

Two of three patients with chronic lymphocytic leukemia achieved partial responses. All five patients with Waldenstrom macroglobulinemia also responded.

The drug was well tolerated among 49 participants. No dose-limiting toxicities or treatment-related deaths were reported. About 43% of patients experienced at least one treatment-related adverse event, most commonly rash and fatigue. Ten patients reported serious adverse events, one of which was considered treatment-related.

The data was presented at the European Hematology Association Annual Congress, according to the company.

Shares of Schrodinger were down nearly 12% in recent trading.

Price: 23.54, Change: -3.15, Percent Change: -11.80